RGNX250117P12500
- 5.50
- 0.000.00%
Regenxbio Newsroom
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $30
BofA Securities Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $22
Regenxbio Price Target Lowered to $22 From $25 at BofA
Novartis Reports Positive Results for Intrathecal Zolgensma
PepGen Stock Craters 35% on FDA Clinical Hold
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $35
RBC Capital Sticks to Its Buy Rating for RegenXBio (RGNX)
Express News | Regenxbio Inc - to Offer and Sell Shares up to $150 Million
Express News | Regenxbio Inc - on Dec 9, Co Enters Sales Agreement With Leerink Partners
Apollo Global Management, Workday to Join S&P 500
Champion Homes to Replace Regenxbio in S&P 600 at Open on 12/23
Express News | S&P Dow Jones Indices: Terreno Realty Corp. and Champion Homes Inc. Will Replace Hudson Pacific Properties Inc. and Regenxbio Inc. in S&P Smallcap 600
REGENXBIO Price Target Cut to $36.00/Share From $40.00 by HC Wainwright & Co.
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $36
Buy Rating on RegenXBio Driven by Positive RGX-202 Trial Results and Strong Approval Prospects
Express News | Regenxbio Inc. : H.c. Wainwright Cuts Target Price to $36 From $40
Barclays Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $50
REGENXBIO Price Target Maintained With a $52.00/Share by Chardan Capital
REGENXBIO Is Maintained at Buy by Chardan Capital
Regenxbio Eyes 2026 Filing for Duchenne Muscular Dystrophy Gene Therapy